CD36 and breast carcinoma: Furthermore, xenografts from lapatinib-resistant breast cancer cells treated with an anti-CD36 antibody were sensitized to lapatinib (Feng et al., 2020), demonstrating a key role of CD36 in the development and therapy response of HER2+ breast tumors.